mYXpression
keyboard_backspaceBack to Home
Contact
64b rue Sully
21000 Dijon
France
Directeur général & Co-fondateur
About us
mYXpression offers highly innovative solutions designed to support biopharmas in the development of their biomedicines targeting autoimmune pathologies. The company has developed a cutting-edge technological platform integrating artificial intelligence and multi-omics analysis. This approach enables precise interpretation of the biological complexity of patients, enabling rigorous identification of individuals eligible or ineligible for Phase 3 clinical trials.
Business offer
mYXpression has developed a patient triage tool that has the ability to use multiple sorting approaches and criteria to identify molecule-specific predictive patterns. mYXpression supports biopharmaceutical companies from initial risk assessment through to on-site recruitment logistics, and ongoing patient triage in clinical routine (via a customized companion diagnostic test or integration with our IVD tests) .
Using proprietary machine-learning techniques powered by petabytes of patient data, mYXpression technology generates unprecedented profiling of patient sub-populations and produces predictions about their likelihood of responding to a given biomedicine.
Activities
- Service
- Immunology
- Inflammation
- Target selection & validation
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Preclinical biomarkers
- Research exploratory Companion biomarkers
- Bioinformatics design
- Bioinformatics prediction & analysis
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Clinical trials
- Phase II
- Phase III
- Phase IV
- Clinical biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Companion biomarkers
- Treatment efficacy
